January 22, 2026
More than 40 members of Azalea Pharma’s quality and regulatory affairs teams completed an advanced pharmacovigilance certification program this month, reinforcing the company’s adverse-event monitoring and reporting standards across all brands. The training covered updated regional reporting requirements and reinforced Azalea’s existing GMP-audited quality processes. Continued investment in staff training remains a core part of Azalea’s approach to patient safety.